finacea
leo pharma a/s - azelaino rūgštis - gelis - 150 mg/g - azelaic acid
ambrisentan aop
aop orphan pharmaceuticals gmbh - ambrisentanas - plėvele dengtos tabletės - 5 mg - ambrisentan
ambrisentan aop
aop orphan pharmaceuticals gmbh - ambrisentanas - plėvele dengtos tabletės - 10 mg - ambrisentan
yaldigo
tillotts pharma ab - mesalazinas - žvakutės - 1 g - mesalazine
evrenzo
astellas pharma europe b.v. - roxadustat - anemia; kidney failure, chronic - antianeminiai preparatai - evrenzo is indicated for treatment of adult patients with symptomatic anaemia associated with chronic kidney disease (ckd).
trittico ac
ideal trade links, uab - trazodono hidrochloridas - pailginto atpalaidavimo tabletės - 150 mg - trazodone
trittico ac
tojaris projektai, uab - trazodonas - pailginto atpalaidavimo tabletės - 150 mg - trazodone
cabometyx
ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - antinavikiniai vaistai - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.
cometriq
ipsen pharma - kabozantinibas - skydliaukės navikai - antinavikiniai vaistai - suaugusių pacientų, sergančių progresuojančia, nerezekuojančia lokaliai išplitusia arba metastazavusia medulinės skydliaukės karcinoma, gydymas.